M
M R Heyman
Publications - 2
Citations - 2821
M R Heyman is an academic researcher. The author has contributed to research in topics: Follicular lymphoma & Galiximab. The author has an hindex of 1, co-authored 1 publications receiving 2737 citations.
Papers
More filters
Journal ArticleDOI
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Peter McLaughlin,Antonio J. Grillo-Lopez,Brian K. Link,Ronald Levy,Myron S. Czuczman,Michael E. Williams,M R Heyman,I. Bence-Bruckler,Christine A. White,Fernando Cabanillas,Vinay K. Jain,A D Ho,John Lister,K Wey,D. Shen,Brian Dallaire +15 more
TL;DR: The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program
Peter McLaughlin,A J Grillo-López,Brian K. Link,Rafael Levy,Myron S. Czuczman,Maura Williams,M R Heyman,I. Bence-Bruckler,Christine A. White,Fernando Cabanillas,Vanita Jain,Anthony D. Ho,John Lister,K Wey,D. Shen,Brian Dallaire +15 more
TL;DR: In this paper , a multi-institutional trial of the chimeric anti-CD20 antibody, IDEC-C2B8, was conducted, where patients with relapsed low grade or follicular lymphoma received an outpatient treatment course of IDEC 375 mg/m2 intravenously weekly for four doses.